ICH Guidelines for New Approach Methodologies

The International Council for Harmonisation (ICH) brings together regulatory authorities from Europe, Japan, United States, Canada, Switzerland, and Brazil alongside pharmaceutical industry experts to develop harmonized technical guidelines. Several ICH guidelines directly impact NAMs acceptance and implementation.

      ICH's Role: ICH guidelines are adopted by FDA, EMA, PMDA, Health Canada, Swissmedic, and ANVISA. A single ICH guideline revision can enable NAMs acceptance across all major pharmaceutical markets simultaneously.
    

Key ICH Guidelines for NAMs

ICH S5(R3) - Reproductive Toxicology

The 2020 revision of S5 was groundbreaking for NAMs acceptance:

Explicitly permits in vitro methods for developmental toxicity screening
Allows NAMs data to inform study design and reduce animal use
Accepts embryo-fetal development studies using human stem cell-derived models
Enables integrated testing strategies combining multiple NAMs

ICH M7(R2) - Mutagenic Impurities

M7 enables computational and in vitro approaches:

Accepts (Q)SAR predictions for mutagenicity assessment
In vitro Ames test as primary genotoxicity screen
Reduces reliance on in vivo follow-up studies
Expert review can override computational predictions

ICH S1 - Carcinogenicity Studies

Ongoing revision (ICH S1B(R1)) addresses NAMs opportunities:

Weight-of-evidence approach reducing 2-year bioassays
Integration of mechanistic data from NAMs
Rasless mouse studies accepted for specific contexts

ICH Safety Guidelines Overview

Guideline	Topic	NAMs Relevance
S1	Carcinogenicity	WoE approach, mechanism data
S2	Genotoxicity	In vitro battery primary screen
S5	Reproductive Toxicity	In vitro screening accepted
S7A/B	Safety Pharmacology	In vitro CV models accepted
S9	Oncology Products	Reduced nonclinical requirements
M3	Nonclinical Safety	Timing and duration guidance
M7	Mutagenic Impurities	(Q)SAR and in vitro accepted

Emerging ICH Initiatives

ICH Q14 - Analytical Procedure Development

Impacts NAMs analytical method validation and lifecycle management.

ICH Expert Working Groups

Active discussions on:

Organ-on-chip standardization
Computational model qualification
Integrated testing strategies
3Rs implementation across guidelines

Using ICH Guidelines

When developing NAMs for regulatory submission:

Identify relevant ICH guidelines for your therapeutic area
Review specific language permitting alternative approaches
Document how your NAM aligns with ICH principles
Reference ICH guidelines in regulatory submissions
Monitor ongoing ICH revisions for new opportunities

← Back to Regulatory Hub | Framework Overview | OECD Guidelines

Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.

Free to share for educational purposes with attribution.